Business
Psoria-Shield, Inc. Enters Into a Purchasing and Distribution Agreement With Medcomp Services, LLC
Psoria-Shield, Inc. Enters Into a Purchasing and Distribution Agreement With Medcomp Services, LLC.
About this update from Wellness Center Usa Inc
[{"type":"text","content":"\n\n Psoria-Light® is first-to-market Targeted Deep NB - UVB/UVA LED Phototherapy device\n SCHAUMBURG, Ill., June 08, 2015 (GLOBE NEWSWIRE) -- Wellness Center USA, Inc. (OTCQB:WCUI) today announced that its wholly-owned subsidiary, Psoria-Shield, Inc. (PSI), has entered into a purchasing and distribution agreement with Medcomp Services, LLC (MCS), a leading specialist in providing innovative medical technology and products, as well as digital based marketing initiatives to focused practices such as Dermatologists, Plastic Surgeons, and Physician Owned Medical Spas. The basis of the agreement will provide for multi-unit purchases of PSI’s targeted phototherapy device, Psoria-Light®. Under the terms of the Agreement, product delivery will commence this month. Medcomp Services, LLC will purchase several Psoria-Light® units for its own use as well as distribute the device to its client base of Physicians, Plastic Surgeons, and Medical Spas. Additionally, Medcomp Services, LLC will use its sales and marketing personnel to provide education and training on Psoria-Light® to its clients. Certain MCS clients in the NYC area are:  Beauty Fix Medspa, Body Cosmetica, Allgenic, and more. “We are excited to be entering into this sales, marketing, and distribution agreement with Psoria-Shield, Inc.,” stated Mark Greenspan, principal of Medcomp Services, LLC. “Our network of physicians who purchase Psoria-Light® will be able to treat and provide relief to a large population of patients suffering from skin disorders such as eczema, psoriasis, and vitiligo,” he added. With the Psoria-Light®, physicians will be able to offer their patients the most advanced NB - UVB/UVA LED treatment available today. This FDA cleared procedure is recognized by many major insurance companies as well as government agencies. Third party awareness organizations, policy makers, and insurers are becoming increasingly aware of the cost benefit of UV phototherapy (targeted or non-targeted) to the patient and the healthcare system as opposed to systemic/biologic drug therapy. The short and long term impact on healthcare system costs associated with systemic/biologic drug side effects can be substantial. “This Agreement will provide exposure and introduce PSI to the leading dermatological practices in th...